Aethlon Medical Inc AEMD
Aethlon Medical Inc (Nasdaq: AEMD) is an oncology medical device company. Its next catalyst on record is NOR-101: Post-merger plan: NOR-101 (IL-13 x IL-18 bispecific) Phase 1a to start Q1 2027 with interim PK and safety data expected by mid-2027. (June 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: NOR-101 — Post-merger plan: NOR-101 (IL-13 x IL-18 bispecific) Phase 1a to start Q1 2027 with interim PK and safety data expected by mid-2027. (June 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Hemopurifier (oncology, Australian safety/feasibility/dose-finding trial) | Solid tumors on anti-PD-1 therapy | device-combination | NA_NON_THERAPEUTIC |
| Hemopurifier (life-threatening viral infections, open IDE / expanded access) | Enveloped viruses (e.g., Ebola) | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other oncology companies
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- NovoCure Ltd NVCR
- Personalis, Inc. PSNL
- AnaptysBio, Inc. ANAB
- Freenome, Inc. FRNM
- Alpha Tau Medical Ltd. DRTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.